Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine
Stock Information for Axsome Therapeutics Inc.
Loading
Please wait while we load your information from QuoteMedia.